5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice
Salvage chemotherapy for patients with unresectable pancreatic cancer (UR-PC) who have been treated with gemcitabine and nab-paclitaxel (GnP), and 5-fluorouracil (5-FU)/l-leucovorin (LV) plus nanoliposomal irinotecan (nal-IRI), has not been fully established. We retrospectively reviewed data from 17...
المؤلفون الرئيسيون: | , , , , , , , , , , , , , |
---|---|
التنسيق: | مقال |
اللغة: | English |
منشور في: |
MDPI AG
2022-04-01
|
سلاسل: | Current Oncology |
الموضوعات: | |
الوصول للمادة أونلاين: | https://www.mdpi.com/1718-7729/29/4/216 |